Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Jennifer Ravenscroft"'
Autor:
Darren P Baker, Carlos Navas, Carolina Ionete, Mar Tintoré, Zia Choudhry, Rafael Arroyo, David Rog, Nadia Daizadeh, Aaron Boster, Bernard M. J. Uitdehaag, Sara Eichau, Lívia Sousa, Topaz investigators, Jennifer Ravenscroft, Volker Limmroth, Carlo Pozzilli, Alexey Boyko, Ann D Bass, Care-Ms I, Care-Ms Ii, Camms, Daniel Pelletier
Publikováno v:
Multiple Sclerosis and Related Disorders, 49:102717. Elsevier
Scientia
Bass, A D, Arroyo, R, Boster, A L, Boyko, A N, Eichau, S, Ionete, C, Limmroth, V, Navas, C, Pelletier, D, Pozzilli, C, Ravenscroft, J, Sousa, L, Tintoré, M, Uitdehaag, B M J, Baker, D P, Daizadeh, N, Choudhry, Z, Rog, D & CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators 2021, ' Alemtuzumab outcomes by age : Post hoc analysis from the randomized CARE-MS studies over 8 years ', Multiple Sclerosis and Related Disorders, vol. 49, 102717 . https://doi.org/10.1016/j.msard.2020.102717
Scientia
Bass, A D, Arroyo, R, Boster, A L, Boyko, A N, Eichau, S, Ionete, C, Limmroth, V, Navas, C, Pelletier, D, Pozzilli, C, Ravenscroft, J, Sousa, L, Tintoré, M, Uitdehaag, B M J, Baker, D P, Daizadeh, N, Choudhry, Z, Rog, D & CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators 2021, ' Alemtuzumab outcomes by age : Post hoc analysis from the randomized CARE-MS studies over 8 years ', Multiple Sclerosis and Related Disorders, vol. 49, 102717 . https://doi.org/10.1016/j.msard.2020.102717
Alemtuzumab; Efficacy; Safety Alemtuzumab; Eficacia; Seguridad Alemtuzumab; Eficàcia; Seguretat Background Alemtuzumab significantly improved clinical and MRI outcomes vs. subcutaneous interferon beta-1a (SC IFNB-1a) in the CARE-MS trials (NCT005303
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83728c1f13a64a694c1b1f493edb2e15
https://hdl.handle.net/10668/17008
https://hdl.handle.net/10668/17008
